Enlivex Therapeutics Ltd. (ENLV) vs Lexaria Bioscience Corp. (LEXX)
A side-by-side comparison of Enlivex Therapeutics Ltd. and Lexaria Bioscience Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENLV
Enlivex Therapeutics Ltd.
$0.34HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
LEXX
Lexaria Bioscience Corp.
$3.24HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ENLV vs LEXX
growth of $100 · dividends reinvested · last 6yENLV -99.8% (-63.4%/yr)LEXX -95.9% (-41.2%/yr)LEXX compounded faster over this window
Log scale — wide-divergence pair
ENLV LEXX
ENLV vs LEXX: by the numbers
- •ENLV is the larger company ($6M vs $5M market cap).
- •Both run net losses; ENLV's is the smaller (0.00% vs -3985.58% net margin).
Metrics side by side
Valuation
| Metric | ENLV | LEXX |
|---|---|---|
| P/E ratio | 0.00 | N/A |
| P/S ratio | N/A | 27.60 |
| P/B ratio | 0.00 | 1.13 |
Profitability
| Metric | ENLV | LEXX |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -1683.01% |
| Net margin | 0.00% | -3985.58% |
| ROE | 105.35% | -163.18% |
| ROIC | -0.32% | -175.26% |
Growth (annualized)
| Metric | ENLV | LEXX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.92% |
| Total return CAGR (5Y) | -69.81% | -50.86% |
Frequently asked
- How have ENLV and LEXX total returns compared?
- Over the past 5 years, ENLV delivered -69.81% and LEXX delivered -50.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Enlivex Therapeutics ROELexaria Bioscience ROEEnlivex Therapeutics operating marginLexaria Bioscience operating marginEnlivex Therapeutics revenue growthLexaria Bioscience revenue growthEnlivex Therapeutics free cash flowLexaria Bioscience free cash flow
Enlivex Therapeutics & Lexaria Bioscience appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.